Nymox Pharmaceutical Corporation (NASDAQ:NYMX) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a report released on Friday.

Nymox Pharmaceutical Corporation (NYMX) opened at 3.47 on Friday. The firm’s 50-day moving average is $3.93 and its 200 day moving average is $3.81. The company’s market cap is $178.80 million. Nymox Pharmaceutical Corporation has a 52-week low of $2.00 and a 52-week high of $5.79.

COPYRIGHT VIOLATION NOTICE: “Nymox Pharmaceutical Corporation (NYMX) Upgraded by ValuEngine to Hold” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/11/nymox-pharmaceutical-corporation-nymx-upgraded-by-valuengine-to-hold.html.

In other Nymox Pharmaceutical Corporation news, Director James George Robinson bought 10,000 shares of the company’s stock in a transaction dated Thursday, August 3rd. The stock was acquired at an average price of $3.73 per share, with a total value of $37,300.00. Following the completion of the acquisition, the director now directly owns 3,077,550 shares of the company’s stock, valued at $11,479,261.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have bought 152,500 shares of company stock valued at $583,370 in the last ninety days. Insiders own 54.00% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. TIAA CREF Investment Management LLC acquired a new stake in Nymox Pharmaceutical Corporation during the second quarter worth about $329,000. Teachers Advisors LLC acquired a new stake in Nymox Pharmaceutical Corporation during the second quarter worth about $218,000. Bank of New York Mellon Corp acquired a new stake in Nymox Pharmaceutical Corporation during the second quarter worth about $323,000. Wedbush Securities Inc. raised its stake in Nymox Pharmaceutical Corporation by 30.6% in the second quarter. Wedbush Securities Inc. now owns 234,692 shares of the biopharmaceutical company’s stock worth $1,033,000 after buying an additional 55,000 shares during the last quarter. Finally, Rhumbline Advisers acquired a new stake in Nymox Pharmaceutical Corporation during the second quarter worth about $134,000. 1.78% of the stock is owned by institutional investors and hedge funds.

Nymox Pharmaceutical Corporation Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with MarketBeat.com's FREE daily email newsletter.